Q2 2026 MannKind Corp Earnings Call Transcript
Key Points
- MannKind Corp (MNKD) achieved all three major 2026 catalysts: Afrezza pediatric approval, Furo6 ReadyFlow approval, and positive Phase 1b data for nintedanib DPI in IPF patients.
- Afrezza pediatric launch shows strong early momentum, with all 20 priority accounts writing prescriptions and one in three of the top 100 pediatric rapid-acting insulin prescribers already prescribing.
- Furo6 revenue grew 43% quarter-over-quarter, driven by a 49% increase in units sold, with nephrology sales up 67%.
- Marketed products revenue grew 111% year-over-year, now exceeding royalty revenue, demonstrating successful diversification.
- The nintedanib DPI Phase 1b study showed a clean safety profile with zero serious adverse events, zero bronchospasms, and zero discontinuations, supporting chronic use.
- Furo6 ReadyFlow, the only IV-equivalent diuretic auto-injector, is expected to launch within three weeks, with a 70% gross margin improvement over the on-body infuser.
- The company raised $50 million in a pipe financing, providing pro forma cash of $161 million to support launches and development.
- MannKind Corp (MNKD) reported a GAAP net loss of $19 million in Q2 2026, compared to net income of $0.7 million in the prior year quarter.
- The company expects Q2 to be the highest quarter for manufacturing-related revenues, with annual revenues in line with the prior year, indicating potential revenue decline in the second half.
- Afrezza adult sales saw softness due to resource reallocation to pediatrics, with a year-over-year decline.
- Furo6 gross-to-net adjustments increased to 29% in Q2, offsetting some revenue growth.
- The company will incur a $45 million CVR payment in Q3, impacting cash flow.
- The nintedanib DPI Phase 1b study reported a 39% cough rate, though mostly mild and transient.
- Furo6 guidance implies a significant second-half revenue ramp, which may be challenging given patient affordability issues and inventory transitions.
Good afternoon and welcome to the Mankind Corporation Second Quarter 2026 Financial Results Earnings Call.
As a reminder, this call is being recorded on August 5th, 2026 and will be available for replay on the Mankind Corporation website shortly after this call for approximately 90 days.
This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations.
For further information on the company's risk factors, please see the form 10Q for the period ended June 30, 2026, the earnings release, and the slides prepared for this presentation.
Joining us today from Mankind, our Chief Executive Officer, Michael Castagna and Chief Financial Officer, Chris Prentice. I'd now like to turn the conference over to Mr. Castagna. Please go ahead, sir.
Thank you, operator, and good afternoon, everyone.
Thank you for joining us for our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
